GlaxoSmithKline Pharmaceuticals Limited announced a change in its management. The Board of Directors, in a meeting held on March 2, 2026, approved the appointment of Mr. Ronojit Biswas (DIN 07684843) as the Whole-Time Director & Chief Financial Officer (CFO) for a term of three years, effective April 1, 2026. Mr. Biswas is not related to any existing Directors and is not debarred by SEBI or any other authority. He brings over 25 years of experience with GSK across international markets, including India, Vietnam, Singapore, Brazil, and the UK. His previous roles include Senior Finance Director – Global Product Strategy in Singapore, CFO for GSK's Brazil and Vietnam businesses, and Regional Controller for GSK's International region. Concurrently, Mr. Juby Chandy, the current CFO, will transition to a new role within the GSK Group. He will step down as Whole-Time Director and CFO effective March 11, 2026. The company expressed its sincere appreciation for Mr. Chandy's contributions to strengthening the company's financial position and governance. The Board of Directors' meeting commenced at 11:00 am and concluded at 12:00 noon on March 2, 2026.
